

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 14/47* (2006.01)(21) International Application Number:
PCT/US2021/045615(22) International Filing Date:
11 August 2021 (11.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/064,880 12 August 2020 (12.08.2020) US(71) Applicant: **THE BOARD OF TRUSTEES OF THE LE-
LAND STANFORD JUNIOR UNIVERSITY** [US/US];
Building 170, Third Floor, Main Quad, P.O. Box 20386,
Stanford, CA 94305-2038 (US).(72) Inventors: **GIACCIA, Amato, J.**; Building 170, Third
Floor, Main Quad, P.O. Box 20386, Stanford, CA
94305-2038 (US). **MIAO, Yu**; Building 170, Third Floor,
Main Quad, P.O. Box 20386, Stanford, CA 94305-2038(US). **THAKKAR, Kaushik**; Building 170, Third Floor,
Main Quad, P.O. Box 20386, Stanford, CA 94305-2038
(US). **MIZUNO, Kazue**; Building 170, Third Floor, Main
Quad, P.O. Box 20386, Stanford, CA 94305-2038 (US).(74) Agent: **FINE, Isaac M.**; KPPB LLP, 2190 S. Towne Center
Place, Suite 300, Anaheim, CA 92806 (US).(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: SBCMA VARIANTS AND FC FUSION PROTEINS THEREOF




FIGURE 4

(57) Abstract: The invention is directed to novel sBCMA variants and sBCMA variant - Fc fusion proteins, polynucleotides encoding the sBCMA variants and/or sBCMA variant - Fc fusion proteins, methods of making the sBCMA variants and/or sBCMA variant - Fc fusion proteins, and methods of using compositions comprising the sBCMA variants and/or sBCMA variant - Fc fusion proteins, for example, in treating diseases such as tumors/cancers, immunoregulatory disorders, etc.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*